Opus Genetics, Inc.: 10-K filed 2012-03-16
What Opus Genetics, Inc. reported in its annual report filed 2012-03-16 (fiscal FY 2011): 19 published measures, 52 facts as tagged in accession 0001140361-12-016054.
This filing
- Form
- 10-K (annual report)
- Filed
- 2012-03-16
- Fiscal period
- fiscal FY 2011
- Accession
- 0001140361-12-016054 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Opus Genetics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 13,689,648 | USD | |
| At 2010-12-31 | 16,216,184 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 2,983,518 | USD | |
| At 2010-12-31 | 5,820,727 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 10,706,130 | USD | |
| At 2010-12-31 | 10,395,457 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 9,861,488 | USD | |
| At 2010-12-31 | 12,340,239 | USD | |
| At 2009-12-31 | 7,298,032 | USD | |
| At 2008-12-31 | 369,130 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -11,344,950 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -14,022,107 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -2,903,098 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 0 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 0 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 0 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 13,597,474 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 12,688,844 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 10,733,922 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -545,919 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -660,039 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 1,341,825 | USD | 365 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 0 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 0 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 0 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 94,542 | USD | |
| At 2010-12-31 | 123,565 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 638,607 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 584,657 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 497,531 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -16,131,013 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -10,305,909 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -6,465,898 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 12,163,341 | USD | |
| At 2010-12-31 | 15,672,044 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 0 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 0 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 0 | USD | 365 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 16,131,013 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 10,305,909 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 6,465,898 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 11,992,087 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 3,934,701 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 3,176,971 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 95,345,656 | shares | |
| At 2010-12-31 | 84,160,849 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 3,547,829 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 5,990,624 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 2,944,103 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 4,786,063 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -3,716,198 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 3,562,800 | USD | 365 |
Inspect the source
- Entity
- Opus Genetics, Inc. / CIK 0001228627
- Captured
- 2026-09-20T07:46:24.028Z
- SEC response SHA-256
59b3f548361fa5c66fb8bd927bac9bc7dc8822bcce158860c7c4d77974af0a92
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001228627.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))